Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Subspecialties Health Economics and Policy, Pediatric, Retina

Clarity on Global Disparity

Healthcare disparities are a major issue globally, with large portions of the world’s population facing preventable obstacles to high-quality care. Now, socioeconomic status has been highlighted as a major risk of childhood death from retinoblastoma in research from the London School of Hygiene and Tropical Medicine, London, UK (1). In fact, data published in The Lancet Global Health shows that children in low-income countries are 16 times more likely to die from retinoblastoma – the most common eye cancer – in the first three years following diagnosis.

This is the first assessment of global disparities relating to retinoblastoma. Due to the cancer’s rarity, previous data on the disease were quite sparse and heavily focused on high-income countries in North America, Europe, and Oceania, although over 80 percent of patients are located in low- and middle-income countries. In comparison, this study is remarkably extensive, with data gathered from 4,064 patients in 149 countries; it is estimated to include half of all new global retinoblastoma cases in 2017.

Death from retinoblastoma is rare in high-income countries – but the cancer’s 99.5 percent survival rate drops to almost 50 percent in low-income countries. This is not due to lack of essential treatment, because treatment is available in almost all countries and participating centers. So why the disparity?

Early diagnosis and treatment are crucial to retinoblastoma survival, yet patients in countries with poor economic standing tended to present late with advanced disease. Increased awareness of early symptoms of retinoblastoma is needed in low- and middle-income countries so that parents and families can recognize the need to see a clinician when symptoms arise, improve access to prompt diagnosis, and fully engage with existing treatment pathways.

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. Global Retinoblastoma Study Group, Lancet Glob Health, 8, E1128 (2022). DOI: 10.1016/S2214-109X(22)00250-9.
About the Author
Geoffrey Potjewyd

Associate Editor, The Ophthalmologist

The lion’s share of my PhD was spent in the lab, and though I mostly enjoyed it (mostly), what I particularly liked was the opportunity to learn about the latest breakthroughs in research. Communicating science to a wider audience allows me to scratch that itch without working all week only to find my stem cell culture has given up the ghost on the Friday (I’m not bitter). Fortunately for me, it turns out writing is actually fun – so by working for Texere I get to do it every day, whilst still being an active member of the clinical and research community.

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine